Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REBUILDING-2 (RAY1225, NCT06893016)

REBUILDING-2 (RAY1225, NCT06893016)

RAY1225 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
RAY1225
Population
obesity
Official title
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Phase
3
Registry status
recruiting · 2025-06 → 2026-06
Participants
641
Duration
52 weeks
Registry
NCT06893016

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
9 mg Q2Wobesity china52641−22.3 %−22.2 %———————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (2)
  • 9 mg Q2W · weight_tp · HKEX filing
    9mg 组体重较基线降低 22.24%,经安慰剂校正后降低 20.46%
  • 9 mg Q2W · weight_eff · HKEX filing
    补充分析(假想策略)RAY1225 注射液 9mg 组体重较基线降低 22.30%,经安慰剂校正后降低 20.50%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REBUILDING-2 (RAY1225, NCT06893016). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.